Global Health EDCTP3 Key Updates and Milestones
Thirteenth Edition of the EDCTP Forum
The 13th edition of the European & Developing Countries Clinical Trials Partnership (EDCTP) Forum is scheduled to take place from April 5th to April 9th, 2027, at IFEMA Palacio Municipal in Madrid, Spain.
The event will be co-hosted by the Instituto de Salud Carlos III (ISCIII) under the Spanish Ministry of Science, Innovation and Universities and the Fundación CSAI (FCSAI) under the Ministry of Health, and is co-organised by Global Health EDCTP3 and the EDCTP Association.
The forum since its inception has geared itself as a platform for showcasing the latest scientific breakthroughs, highlighting impactful capacity-building efforts, and creating a space for vibrant cross-regional collaboration.
EMA issues positive opinion for new sleep sickness treatment
Acoziborole Winthrop, a single-dose oral treatment against sleeping sickness, has received a positive scientific opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
The development of Acoziborole is the result of a decade-long collaboration between the Drugs for Neglected Diseases initiative (DNDi), Sanofi, and partners in endemic countries. Global Health EDCTP3 and its predecessor EDCTP programmes have been instrumental in building the evidence base for this treatment.
STOP2030 project approved in Ghana
The STOP2030 project, co-funded by Global Health EDCTP3, secures national approval for the ivermectin-albendazole fixed-dose combination, a single-pill treatment effective against all major soil-transmitted helminths.
Ghana has become the first country in the world to approve the fixed-dose combination of ivermectin and albendazole, a new medicine designed to tackle soil-transmitted helminths, a common parasitic infection affecting millions of people in endemic regions of Africa. The Ghana Food and Drugs Authority granted regulatory approval in late December 2025, allowing the medicine to move beyond experimental studies and into clinical and public health use.
Global Health EDCTP3 interviews Dr Delese Mimi
To mark International Women’s Day, EDCTP3 publishes an interview with Dr Delese Mimi. The inaugural Director General of the African Medicines Agency and former EDCTP grant holder, reflects on building strong regulatory systems to advance safe access to medicines across the continent and on the role of women in shaping public health.
Global Health EDCTP3 selects 36 new project proposals
After the conclusion of evaluation of second-stage of the 2025 calls for proposals, Global Health EDCTP3 has selected 36 new global health projects for a contribution of €215 million.
The selected project proposals span across seven topics, divided between research and innovation actions (RIA), coordination and support actions (CSA) and one identified beneficiary action (IBA). Grant agreements with the successful applicants are expected to be signed during the first half of 2026.
